• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Is Continuing Screening Mammography Past Age 75 Cost-Effective?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Schousboe et al. (Annals of Internal Medicine, 2021) estimated the benefits, harms, and cost-effectiveness of extending mammography to age 80, 85, or 90 years

METHODS:

  • Simulation model
  • Population
    • U.S. women aged 65 to 90 years
    • Data derived from SEER program and Breast Cancer Surveillance Consortium
  • Exposure
    • Screening mammography to age 75, 80, 85, or 90 years
  • Comorbidities
    • Scored using Charlson comorbidity score (CCS) | Predicts mortality by classifying and weighting comorbid conditions
  • Primary outcomes
    • Breast cancer death
    • Survival
    • Costs per quality-adjusted life-year (QALY)

RESULTS:

  • Extending biennial mammography from age 75 to 80
    • Averted breast cancer deaths
      • Comorbidity score 0: 1.7 deaths per 1000 women
      • Comorbidity score 1: 1.4 deaths per 1000 women
      • Comorbidity score ≥2: 1.0 deaths per 1000 women
    • Increased days of life gained
      • Comorbidity score 0: 5.8 days per 1000 women
      • Comorbidity score 1: 4.2 days per 1000 women
      • Comorbidity score ≥2: 2.7 days per 1000 women
  • Cost-effectiveness
    • Annual mammography beyond age 75 years was not cost-effective
    • Extending biennial mammography to age 80 years was cost-effective
      • Comorbidity score 0: $54,000 per QALY gained
      • Comorbidity score 1: $65,000 per QALY gained
      • Comorbidity score ≥2: $85,000 per QALY gained
  • Overdiagnosis cases were approximately double the number of deaths averted from breast cancer
    • Comorbidity score 0: 4.0 overdiagnoses per 1000 women
    • Comorbidity score 1: 3.3 overdiagnoses per 1000 women
    • Comorbidity score ≥2: 2.7 overdiagnoses per 1000 women

CONCLUSION:

  • Biennial mammography screening to age 80 is cost-effective especially for women with few comorbidities
  • The authors state

However, the absolute number of averted breast cancer deaths and days of life gained are small, especially for those with comorbidities

Women considering screening beyond age 75 years need to weigh the harms of overdiagnosis versus the potential benefit of averting death from breast cancer 

Learn More – Primary Sources:

Cost-Effectiveness of Screening Mammography Beyond Age 75 Years: A Cost-Effectiveness Analysis

Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

How Effective Is Mammography in Reducing the Number of Advanced Breast Cancer Diagnoses?
Which Mammography Recommendation Results in the Greatest Breast Cancer Mortality Reduction?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site